Search
Vir Biotechnology Inc
VIRAdd to Watchlist
9.900USD
+0.340+3.56%
Market hours （ET）Quotes delayed by 15 min
1.60BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+3.56%
5 Days
-0.50%
1 Month
+9.63%
6 Months
+64.18%
Year to Date
+64.18%
1 Year
+93.74%
Key Figures
9.640Open
10.100High
342.95KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.21%Turnover Ratio
9.560Prev. Close
9.590Low
2.50MTurnover
LossP/E Static
1.96P/B
0.00%Div Yield TTM
-37.95%ROA
11.66052wk High
0.25Volume Ratio
-521.96MNet Profit
161.23MShares
-3.1349EPS TTM
1.66Beta
-47.69%ROE
4.15552wk Low
5.33%Amplitude
99.96%Gross Margin
1.60BMarket Cap
2.60Reward/Risk
3.61%Risk Rate
TradingKey Stock Score of Vir Biotechnology Inc
Currency: USD Updated: 2026-07-01Key Insights
Vir Biotechnology Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 53 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 21.56.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Vir Biotechnology Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Vir Biotechnology Inc Highlights
StrengthsRisks
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. It also has rights to the PRO-XTEN masking platform for oncology and infectious disease.
Growing
The company is in a growing phase, with the latest annual income totaling USD 68.56M.
Undervalued
The company’s latest PE is -3.05, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 130.35M shares, increasing 6.85% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 600.00K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.33.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
21.556
Target Price
+111.54%
Upside Space
Vir Biotechnology Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Vir Biotechnology Inc Info
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. It also has rights to the PRO-XTEN masking platform for oncology and infectious disease.
Ticker SymbolVIR
CompanyVir Biotechnology Inc
CEODe Backer (Marianne)
Websitehttps://www.vir.bio/
Related Instruments
+1.01%
+2.28%
+5.13%
+2.78%
+2.02%
+3.20%
+2.81%
+3.33%
+3.35%
+1.61%
+4.32%
+1.44%
+4.04%
+3.12%
+2.14%
0.00%
+2.90%
+3.31%
+0.39%
+4.40%Popular Instruments
52626.400
+372.100 (+0.71%)
29279.600
-519.700 (-1.74%)
7456.700
-18.800 (-0.25%)
14752.000
-603.000 (-3.93%)
67959.000
-1526.000 (-2.20%)
6349.400
+74.000 (+1.18%)
67.974
+0.006 (+0.01%)
307.228
+12.848 (+4.36%)
194.305
-3.275 (-1.66%)
4105.830
+75.060 (+1.86%)
FAQs
What is the current price of Vir Biotechnology Inc (VIR)?
The current price of Vir Biotechnology Inc (VIR) is 9.56.
What is the symbol of Vir Biotechnology Inc?
The ticker symbol of Vir Biotechnology Inc is VIR.
What is the 52-week high of Vir Biotechnology Inc?
The 52-week high of Vir Biotechnology Inc is 11.66.
What is the 52-week low of Vir Biotechnology Inc?
The 52-week low of Vir Biotechnology Inc is 4.16.
What is the market capitalization of Vir Biotechnology Inc?
The market capitalization of Vir Biotechnology Inc is 1.61B.
Is Vir Biotechnology Inc (VIR) currently rated as Buy, Hold, or Sell?
According to analysts, Vir Biotechnology Inc (VIR) has an overall rating of Buy, with a price target of 21.56.
What is the Earnings Per Share (EPS TTM) of Vir Biotechnology Inc (VIR)?
The Earnings Per Share (EPS TTM) of Vir Biotechnology Inc (VIR) is -3.16.